Skip to main content

Table 2 Lung function measures at screening and baseline (ITT population)

From: Randomised trial of once-daily vilanterol in children with asthma on inhaled corticosteroid therapy

Lung function measures

Placebo

VI 6.25 μg

VI 12.5 μg

VI 25 μg

Total

N = 115

N = 114

N = 113

N = 114

N = 456

Screening

Pre-bronchodilator PEF (L/min)

n

115

114

113

114

456

Mean

185.05

178.35

179.22

177.09

179.94

SD

59.30

55.67

60.57

55.68

57.74

Post-bronchodilator PEF (L/min)

n

115

114

113

114

456

Mean

238.79

232.29

234.54

228.37

233.51

SD

67.41

69.80

69.79

72.29

69.71

Percentage of pre- to post-bronchodilator PEF (%)

n

115

114

113

114

456

Mean

76.95

76.86

75.87

78.02

76.93

SD

9.18

9.57

10.90

8.17

9.50

Pre-bronchodilator FEV1 (L)

n

91

91

97

102

381

Mean

1.405

1.370

1.374

1.361

1.377

SD

0.408

0.423

0.445

0.429

0.426

Post-bronchodilator FEV1 (L)

n

99

98

96

103

396

Mean

1.700

1.702

1.699

1.680

1.695

SD

0.457

0.532

0.465

0.496

0.487

Pre-bronchodilator FEV1 (% predicted)a

n

91

91

97

102

381

Mean

86.83

82.92

85.04

84.08

84.70

SD

19.83

17.00

17.34

16.77

17.73

Post-bronchodilator FEV1 (% predicted)a

n

99

98

96

103

396

Mean

106.81

101.10

104.34

104.58

104.22

SD

20.94

18.47

16.68

19.97

19.15

Baseline

Pre-bronchodilator PEF (L/min)

n

115

114

113

114

456

Mean

186.27

185.08

181.24

179.39

183.00

SD

60.64

59.17

55.19

56.82

57.88

Percentage of pre- to post-bronchodilator PEF (%)

n

115

114

113

114

456

Mean

77.77

79.54

77.58

79.13

78.51

SD

10.49

9.09

10.11

9.77

9.88

Pre-bronchodilator FEV1 (L)b

n

96

91

97

103

387

Mean

1.367

1.408

1.361

1.365

1.374

SD

0.421

0.454

0.398

0.398

0.416

Pre-bronchodilator FEV1 (% predicted)a,b

n

96

91

97

103

387

Mean

84.37

83.99

85.43

85.75

84.91

SD

19.35

16.99

17.66

18.38

18.08

  1. FEV 1 forced expiratory volume in one second, ITT intention-to-treat, PEF peak expiratory flow, SD standard deviation, VI vilanterol
  2. a% predicted FEV1 data are posthoc analyses
  3. bThree children had post-dose FEV1 at baseline and were not included in any FEV1 secondary endpoint analyses